Atrial Fibrillation Articles & Analysis

VANCOUVER, B.C. – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, announced today that it has raised an undisclosed amount in a new financing round. The financing was led by funds and accounts advised by T. Rowe Price Associates, Inc., and included participation from other new and existing Kardium shareholders. Kardium was ...

By Kardium Inc.

VANCOUVER, British Columbia — Kardium Inc. today announced that the Globe® Mapping and Ablation System has successfully demonstrated safety and efficacy in the GLOBAL-AF study. The results of the study were published in the Journal of Cardiovascular Electrophysiology. The study demonstrated a 76% percent freedom from atrial fibrillation at 12 months after a single treatment with the ...

By Kardium Inc.

Coala-Life Group AB (publ), a leading company in cloud-based remote monitoring of heart and lung diseases, announces today that the TITAN-DM study – a clinical observational study aimed at increasing knowledge about the incidence of atrial fibrillation in people with diabetes – is now fully recruited with 600 participants. The study participants are followed with Coala Heart Monitor ...

By Coala Life Inc.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in the upcoming Canaccord 41st Annual Growth Conference. AtriCure’s management is scheduled to present on Wednesday, August 11, 2021, at 8:00 a.m. Eastern Time. Interested parties may ...

By AtriCure, Inc.

Last week (23-25th September) took place the workshop Atrial Signals 2021 http://www.atrial-signals.kit.edu/ at the Karlsruhe Institute of Technology (KIT), thanks to the joint collaboration of the Institute of Biomedical Engineering (IBT) and the Städtisches Klinikum Karlsruhe. Andreu Climent, CEO of Corify Care presented Acorys, our Non-invasive Electrocardiographic Imaging device of the ...

By Corify Care SL

Adagio Medical, Inc. (Adagio) today announced it has enrolled the first patient in its iCLAS™ Investigational Device Exemption (IDE) trial. The FDA approved study aims to evaluate the safety and efficacy of Adagio’s ultra-low temperature intelligent Continuous Lesion Ablation System (iCLAS) in the treatment of persistent atrial fibrillation (PsAF). Data will be used to support a ...

By Adagio Medical, Inc.

AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage (LAA) management, today announced that the company will be participating in upcoming investor conferences. AtriCure is scheduled to present at the Stifel 2021 Virtual Healthcare Conference, on Wednesday, November 17, 2021. Management is scheduled to present at 8:40 ...

By AtriCure, Inc.

A recent study confirms the high accuracy of the Uscom BP+ central blood pressure monitor for detection of the dangerous cardiac rhythm abnormality Atrial Fibrillation (AF) in a primary care setting. This result confirms that BP+ suprasystolic oscillometry is 94% effective for detection of AF in home care environments and may be used as a screening investigation. ...

By Uscom Ltd

(Seattle, WA – November 17, 2020) – Chief Medical Officer of Bardy Diagnostics and Clinical Professor of Medicine University of Washington Professor Gust H. Bardy sat down with Trudie Lobban, MBE, Founder and CEO of Arrhythmia Alliance, a non-profit organization dedicated to improving the diagnosis, treatment, and quality of life for all those affected by arrhythmias, to discuss the ...

By Bardy Diagnostics, Inc.

VANCOUVER, British Columbia – Kardium Inc. has received CE mark approval for its Globe Mapping and Ablation System – the most complete solution for the treatment of atrial fibrillation (AF). AF is the world’s most common heart rhythm disorder, affecting more than 37 million people. This approval allows Kardium to begin commercial sales of the Globe System in Europe. “This ...

By Kardium Inc.

CoreMap announced today it has completed a $10.5 million Series A financing led by Qure Ventures. The round included both existing investors such as Ronny Ginor, MD of Fifth Focus/HRMG Investments and Orbimed Venture Partners, and a diverse group of new strategic, corporate and financial partners. CoreMap was founded in 2016 by Dr. Peter Spector and based on his groundbreaking work concerning the ...

By CoreMap Inc.

VANCOUVER, British Columbia – Kardium Inc., developer of the Globe® Mapping and Ablation System for the treatment of atrial fibrillation, has raised US $115 million in a new financing round. The round is led by Fidelity Management & Research Company LLC., together with follow-on participation by funds and accounts advised by T. Rowe Price Associates, Inc. The new financing will be ...

By Kardium Inc.

The OCEANIC-AF (atrial fibrillation) study with asundexian is part of the Phase III OCEANIC clinical trial program enrolling more than 27,000 patients in over 40 countries Asundexian is being evaluated as a potential improved treatment option in stroke prevention and could be part of an entirely new class of treatment options in thrombosis management that aims to uncouple efficacy from ...

By Bayer AG

iRhythm Technologies, Inc. is excited to announce the addition of a Clinical Resource Center (CRC) to its website. The CRC was designed to make it easy for clinicians to access clinical evidence, on-demand webinars, and case studies through one centralized location. Clinicians will use the CRC as a gateway to published clinical articles. Summaries of significant ...

By Zio by iRhythm Technologies, Inc.

Johnson & Johnson MedTech* announced today that Biosense Webster, Inc., a worldwide leader in the science and technology of cardiac arrhythmia treatment, enrolled the first patients in its admIRE clinical study in the United States. admIRE is a prospective, multi-center, non-randomized study that will enroll more than 400 patients in the U.S. to evaluate the safety and effectiveness of ...

By Johnson & Johnson Medical Devices Business Services, Inc.

SAN CARLOS, California, September 20, 2021 — Galaxy Medical announced today the initiation of the SPACE-AF study with enrollment of the first two patients at Southlake Regional Health Centre in Newmarket, Canada. In the study, the CENTAURI Pulsed Electric Field (PEF) ablation system will be used to ablate both the pulmonary veins and posterior walls in patients with persistent atrial ...

By Galaxy Medical

The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke events in patients with atrial fibrillation as well as patients with a non-cardioembolic ischemic stroke or high-risk transient ischemic attack involving up to 30,000 patients Bayer drives the development of its FXIa inhibitor, with the goal of offering a ...

By Bayer AG

More than a decade after first earning the FDA’s sign-off for its Zio ECG patch, iRhythm is still churning out data to prove beyond a shadow of a doubt the heart monitor’s ability to spot atrial fibrillation and other arrhythmias as early as possible. The latest bit of proof came in the form of a trio of studies presented at the American College of Cardiology’s annual scientific ...

By Zio by iRhythm Technologies, Inc.

iRhythm Technologies has presented new data on its Zio wearable cardiac monitoring device at the American College of Cardiology (ACC) 71st Annual Scientific Session & Expo, building the clinical case for its devices. One study used Zio AT for monitoring patients who were taken to hospital after fainting. By using the device to monitor patients after discharge, the physicians reduced ...

By Zio by iRhythm Technologies, Inc.

Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), today announced that the U.S. Food and Drug Administration approved a modification of labeling for the Optimizer Smart medical device, allowing the removal of “normal sinus rhythm” (NSR) from the indications for use statement. Since patients are no longer ...

By Impulse Dynamics